Search This Blog

Thursday, January 24, 2019

Ironwood upgraded to Neutral from Underweight at JPMorgan


JPMorgan analyst Eric Joseph upgraded Ironwood Pharmaceuticals to Neutral and raised his price target for the shares to $13 from $11.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)